Tarsus Pharmaceuticals, Inc. (TARS) Stock Price & How to Invest

Last updated November 2026

Short answer

Tarsus Pharmaceuticals (Nasdaq: TARS) is a commercial-stage eye-care biopharma whose revenue comes almost entirely from XDEMVY, the first FDA-approved drug for Demodex blepharitis. Investing in it means betting on one fast-growing but single-product franchise, so the picture rides on XDEMVY's continued prescription growth, its reimbursement setup, and how a June 2026 short-seller allegation about copay practices plays out. In September 2026 it also bought Alkeus Pharmaceuticals, adding a Phase 3 Stargardt disease drug. Third-quarter XDEMVY sales hit a record of about $195 million and management raised 2026 guidance, and the stock closed at $74.50 on November 20, 2026, down about 8% year to date and about 3% over twelve months.

TARS stock price

As of 2026-11-20, Tarsus Pharmaceuticals, Inc. (TARS) last closed at $73.01, down 8.3% over the past year. Over the past 52 weeks it has traded between $56.11 and $90.78.

TARS last close
$73.01
1 day
-6.00%
1 month
+3.56%
1 year
-8.35%
52-week range
$56.11 to $90.78
Last close
2026-11-20

Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or Tarsus Pharmaceuticals, Inc.'s investor relations page. Walnut is informational, not investment advice.

TARS key stats

At $73.01 on November 20, 2026, Tarsus Pharmaceuticals, Inc. (TARS) has a market cap of $3.6B.

Market cap
$3.6B
P/E (forward)
339.6
Price to book
34.6
Beta
0.33

Market cap, P/E and yield are measured at the $73.01 price on November 20, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.

What's new with Tarsus Pharmaceuticals, Inc. (TARS)?

The last two weeks for Tarsus Pharmaceuticals, Inc., as of November 22, 2026: the price move, the next earnings date, what the company filed with the SEC, and what analysts changed.

  • TARS closed at $73.01 on November 20, 2026, down 9.1% over the past five trading days (from $80.28).

Tarsus Pharmaceuticals, Inc. filed no current, quarterly or annual report with the SEC in the last two weeks.

Prices are daily closes from Yahoo Finance. Filings are read from SEC EDGAR every six hours. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.

Tarsus Pharmaceuticals, Inc. (TARS) latest quarter

Tarsus Pharmaceuticals reported revenue of $195 million for Q3 2026, up 64% from a year earlier (Tarsus Pharmaceuticals, Nov 3, 2026).

Revenue
$195 million
up 64% from a year earlier
Diluted EPS
-$14.40
n/a
Net income
-$668 million
n/a

Source: Tarsus Pharmaceuticals Q3 2026 results, Nov 3, 2026. Full earnings breakdown

What does Tarsus Pharmaceuticals, Inc. (TARS) do?

Tarsus Pharmaceuticals is a commercial-stage biopharmaceutical company focused on therapeutic eye care. Its business is anchored by XDEMVY (lotilaner ophthalmic solution 0.25%), the first and only FDA-approved treatment that directly targets the Demodex mites behind Demodex blepharitis, a common and previously under-treated eyelid condition. The company delivered roughly 400,000 bottles of XDEMVY in 2025 (up from about 163,000 in 2024) and is building a lotilaner-based pipeline that includes TP-04 for ocular rosacea and TP-05 for potential prevention of Lyme disease, with topline data for both expected in the first half of 2027. In September 2026 Tarsus completed its acquisition of privately held Alkeus Pharmaceuticals, whose lead asset, gildeuretinol acetate (ALK-001), is an oral drug in a global Phase 3 trial (NORTHSTAR) for Stargardt disease, an inherited retinal disease with no FDA-approved therapy; topline data is expected in 2029, and the deal terms were not disclosed in the closing announcement.

The investment picture is a classic single-product growth story. XDEMVY net product sales grew more than 85% year over year in the first quarter of 2026, gross margins run around 93%, and management targets more than $2 billion in eventual peak sales, yet the company still runs near breakeven and depends heavily on one drug. In late June 2026, short-seller Culper Research disclosed a short position and alleged that XDEMVY sales lean on an improper Medicare copay-assistance arrangement and that the addressable market is far smaller than the company claims, which added a new layer of controversy on top of the usual biopharma reimbursement and competition risks.

Since then the numbers have kept growing. Second-quarter 2026 revenue was about $174 million, up roughly 69% year over year, with a net loss of about $18.6 million. The third quarter, reported November 3, set a record: XDEMVY net product sales of about $194.6 million, up nearly 64% year over year, and management raised full-year 2026 XDEMVY guidance to $715 to $730 million. The reported net loss jumped to about $668 million because of roughly $632 million of acquired in-process R&D charges tied to the Alkeus and Irenix acquisitions, a non-cash accounting item; the loss of $0.87 per share compared with a consensus near $1.77 that had expected those charges. Cash and equivalents stood at about $310 million at the end of September. At $74.50 on November 20, 2026, TARS was down about 8% year to date and 3% over twelve months but up about 9% over the past month, within a 52-week range of $53.89 to $91.53, for a market value of about $3.7 billion. After the report Mizuho raised its price target to $102 and Oppenheimer to $103, both with outperform ratings.

What's driving Tarsus Pharmaceuticals, Inc. (TARS)?

1. XDEMVY prescription growth

XDEMVY net product sales rose more than 85% year over year in Q1 2026 to about $145 million, driven by expanding prescriber adoption and direct-to-consumer campaigns, and reached a record of about $194.6 million in Q3 2026, up nearly 64%. Management raised full-year 2026 XDEMVY guidance to $715 to $730 million with the third-quarter report, and consensus total revenue for 2026 sits near $742 million, rising to about $942 million in 2027. The core question is how long high double-digit growth can persist as the easiest-to-reach prescribers are converted; growth has already eased from above 85% to the mid-60s.

2. Large, under-penetrated indication

Demodex blepharitis is estimated to affect tens of millions of Americans, and XDEMVY remains the only FDA-approved therapy that targets the underlying mites. Tarsus frames a path to more than $2 billion in peak sales on the back of that penetration runway. A short-seller has publicly disputed the size of the realistic addressable market, so this driver is also contested.

3. High-margin economics

XDEMVY carries product gross margins around 93% (about 84% gross margin on total revenue over the trailing twelve months), and the Q1 2026 net loss narrowed sharply to about $7 million as revenue scaled against a largely fixed commercial base. Acquisitions broke that pattern: Q3 2026 included about $632 million of acquired in-process R&D charges, producing a net loss of about $668 million, and the new programs add trial costs. Consensus models a 2026 loss of about $15 per share, nearly all from those charges, then roughly breakeven EPS of about $0.22 in 2027. Free cash flow was positive at about $80 million over the trailing twelve months, which is the better gauge of the underlying operating leverage.

4. Pipeline optionality and the Alkeus deal

Beyond XDEMVY, Tarsus is advancing TP-04 for ocular rosacea and TP-05, an oral tablet studied for Lyme disease prevention, both using the same lotilaner molecule. Topline data for these Phase 2 programs is expected in the first half of 2027, and management has said a TP-04 Phase 3 could start in late 2027 or 2028. The September 2026 Alkeus acquisition added a later-stage bet: gildeuretinol acetate (ALK-001), an oral Phase 3 candidate for Stargardt disease with Breakthrough Therapy, Orphan Drug, Fast Track and Rare Pediatric Disease designations, whose NORTHSTAR study the company now positions as its main registration trial, with topline data not expected until 2029. A separate Irenix acquisition brought IRX-101, with a Phase 3 start expected in the first half of 2027. Success would diversify a currently one-product company, though all of these carry standard clinical risk.

What are the risks to Tarsus Pharmaceuticals, Inc. (TARS)?

The overwhelming risk is single-product concentration: essentially all revenue comes from XDEMVY, so any slowdown in prescriptions, coverage, or pricing hits the whole company. In late June 2026, short-seller Culper Research alleged that XDEMVY sales depend on donations routed to a blepharitis copay fund in a way it argues may violate the federal Anti-Kickback Statute, and it claimed the true addressable market is roughly a fifth of company estimates; these are unproven allegations, but they introduce regulatory, reimbursement, and reputational uncertainty. Tarsus also depends on intellectual property licensed from Elanco, faces gross-to-net and Medicare Part D dynamics that can compress net pricing, and still runs near breakeven with a history of losses. Cheaper off-label alternatives and potential future competitors, plus binary Phase 2 pipeline readouts, round out the risk set. The Alkeus and Irenix purchases add integration and clinical risk in new therapeutic areas, already cost about $632 million in acquired R&D charges in the third quarter, and bring trial costs that will weigh on reported earnings for years; cash fell to about $310 million at the end of September. Insider share sales in September 2026 and a second-quarter EPS miss also weighed on sentiment before the third-quarter beat.

What is the Tarsus Pharmaceuticals, Inc. (TARS) forecast?

9 analysts publish price targets on TARS, averaging $103.44 as of November 2026, or +41.7% against the $73.01 share price on November 20, 2026. The published targets run from $88.00 to $116.00, a narrow spread, and the ratings split 10 buy, 0 hold, 0 sell. Over the last six months there have been 4 raises and 2 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full TARS forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

Is TARS a buy or a sell?

We give no verdict on Tarsus Pharmaceuticals, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. XDEMVY prescription growth. XDEMVY net product sales rose more than 85% year over year in Q1 2026 to about $145 million, driven by expanding prescriber adoption and direct-to-consumer campaigns, and reached a record of about $194.6 million in Q3 2026, up nearly 64%. The most optimistic published target, $116.00, assumes this works close to its best case.

The case against. The overwhelming risk is single-product concentration: essentially all revenue comes from XDEMVY, so any slowdown in prescriptions, coverage, or pricing hits the whole company. The most pessimistic target, $88.00, is roughly what TARS is worth if this bites instead.

Read the full bull and bear case on TARS, including what would have to change to break either one. Walnut is not an investment adviser.

Has Tarsus Pharmaceuticals, Inc. (TARS) split its stock?

No. Tarsus Pharmaceuticals, Inc. (TARS) has not split its stock in the last 10 years. The statement covers only the window we check, so an older split in the company’s history is possible. It also matters less than it once did: fractional shares mean a high price per share no longer keeps smaller investors out, which removed most of the practical reason to split.

How is Tarsus Pharmaceuticals, Inc. (TARS) valued?

Market cap, P/E and dividend yield at today's price are in the TARS key stats above. The business figures below come from Tarsus Pharmaceuticals, Inc.'s reported results as of November 2026 and change when it next reports.

  • Revenue (TTM): ~$682M
  • Q3 2026 XDEMVY net sales: ~$195M (+~64% YoY)
  • Q3 2026 net loss: ~($668M) incl. ~$632M acquired IPR&D; ($0.87)/sh vs ~($1.77) est.
  • 2026 XDEMVY guidance: $715M to $730M (raised Nov 3)
  • Free cash flow (TTM): ~$80M
  • Cash / debt (Sept 30): ~$310M / ~$89M

As of November 2026: As of November 20, 2026 TARS traded near $74.50 with a market capitalization around $3.7 billion, roughly 5.4x trailing revenue. Trailing earnings are swamped by the one-time acquired R&D charges, so sales growth, gross margin and free cash flow are the more usable anchors, and the forward P/E (about 350x on 2027 consensus EPS of $0.22) mainly shows how thin expected profit still is. The nine analysts in Yahoo Finance's sample carry a mean target near $103.44.

Who competes with Tarsus Pharmaceuticals, Inc. (TARS)?

Off-label and procedural alternatives

Because XDEMVY is the only FDA-approved Demodex blepharitis drug, its practical competition is largely non-pharmaceutical: tea tree oil lid scrubs, hypochlorous acid cleansers, compounded ivermectin or metronidazole, and in-office procedures like BlephEx and IPL. These are cheaper and familiar to eye-care providers, though none of them is FDA-approved for Demodex blepharitis.

Broader ophthalmology and dry-eye franchises

Large eye-care players such as AbbVie (Allergan), Bausch + Lomb, Alcon, and Harrow compete for the same ophthalmologist and optometrist attention and prescribing budget with dry-eye and lid-margin products, even where they do not directly treat Demodex mites. They have deeper commercial infrastructure and existing payer relationships.

Future pipeline entrants

The commercial success of XDEMVY invites potential future competition in Demodex blepharitis and adjacent lid diseases, and Tarsus's own pipeline candidates (TP-04, TP-05) will eventually face established players in ocular rosacea and Lyme prevention. New FDA-approved rivals would erode XDEMVY's current sole-approved-therapy advantage.

What stocks are similar to Tarsus Pharmaceuticals, Inc. (TARS)?

Other names that sit close to TARS: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. They are useful if you want to spread one thesis across several tickers.

How to invest in Tarsus Pharmaceuticals, Inc. (TARS)

There are three common ways to get TARS exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so TARS sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where TARS fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

The bottom line on Tarsus Pharmaceuticals, Inc. (TARS)

TARS is a rapidly scaling eye-care story where the upside case rests on XDEMVY reaching blockbuster sales (revenue ran about $682 million over the trailing twelve months to September 2026, and 2026 guidance was raised to $715 to $730 million) and the risk case rests on that same concentration, open questions about how those sales are funded, and newly acquired pipeline programs whose roughly $632 million of acquired R&D charges turned the third quarter into a large GAAP loss and whose main retina readout will not come until 2029.

More on Tarsus Pharmaceuticals, Inc. (TARS)

Whether TARS is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is TARS a buy or a sell?, and where the stock could go from here in the TARS stock forecast.

For income investors, whether TARS pays a dividend and how the payout looks is covered in does TARS pay a dividend? And to weigh TARS against a peer, read the full side-by-side comparisons: TARS vs ABBV and TARS vs BLCO.

Wondering how TARS fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about Tarsus Pharmaceuticals, Inc.

Ask Walnut's AI anything about TARS and see how it fits what you own.

FAQ

What does Tarsus Pharmaceuticals do?

+

Tarsus is a commercial-stage biopharmaceutical company focused on eye care. Its main product, XDEMVY, is the first FDA-approved treatment for Demodex blepharitis, a common eyelid condition caused by mites. It is also developing lotilaner-based candidates for ocular rosacea and Lyme disease prevention.

How does Tarsus make money?

+

Almost all revenue comes from XDEMVY net product sales, supplemented by smaller license and collaboration revenue. In Q1 2026 the company reported about $162 million in total revenue, of which roughly $145 million was XDEMVY, and Q3 2026 revenue reached about $195 million. Full-year 2025 revenue was about $451 million. Total revenue over the twelve months to September 2026 was about $682 million, and 2026 XDEMVY guidance is $715 to $730 million.

Is Tarsus Pharmaceuticals profitable?

+

Not on a GAAP basis. The company has a history of losses: its Q1 2026 net loss narrowed to about $7 million as XDEMVY revenue scaled against high (about 93%) gross margins, the Q2 2026 loss was about $18.6 million, and Q3 2026 showed a net loss of about $668 million because of roughly $632 million of non-cash acquired R&D charges from the Alkeus and Irenix deals. Free cash flow was positive at about $80 million over the trailing twelve months, and consensus expects EPS near breakeven (about $0.22) in 2027.

What is XDEMVY and why does it matter to the stock?

+

XDEMVY (lotilaner ophthalmic solution) is the only FDA-approved drug that targets the Demodex mites behind Demodex blepharitis. It generates essentially all of Tarsus's revenue, so the stock's direction is closely tied to XDEMVY prescription growth, reimbursement, and peak-sales potential.

What is the short-seller report about Tarsus?

+

In late June 2026, Culper Research disclosed a short position and alleged that XDEMVY sales rely on an improper Medicare copay-assistance arrangement that it argues may breach the Anti-Kickback Statute, and that the addressable market is much smaller than the company claims. These are unproven allegations, and the company disputes such framing, but they added uncertainty and volatility.

Who are Tarsus Pharmaceuticals' competitors?

+

XDEMVY has no direct FDA-approved pharmaceutical competitor for Demodex blepharitis. Its practical competition includes off-label options like tea tree oil scrubs and compounded ivermectin, procedures such as BlephEx and IPL, and broader eye-care franchises from AbbVie, Bausch + Lomb, and Alcon competing for prescriber attention.

How big could XDEMVY get?

+

Management has framed a path to more than $2 billion in eventual peak annual sales, citing tens of millions of potential Demodex blepharitis patients in the US. That figure is an internal target, not a guarantee, and a short-seller has publicly argued the realistic market is far smaller.

What is the biggest risk with TARS stock?

+

Single-product concentration is the core risk: XDEMVY drives essentially all revenue, so any setback in prescriptions, payer coverage, pricing, or the recent copay-practice allegations could hit the whole company. Reliance on licensed IP, the newly acquired Alkeus and Irenix programs and their costs, a cash balance that fell to about $310 million after those deals, and binary pipeline readouts add further risk. Walnut is not an investment adviser.

Why did Tarsus buy Alkeus Pharmaceuticals?

+

Tarsus completed the acquisition on September 4, 2026, after announcing it on August 6. Alkeus brings gildeuretinol acetate (ALK-001), an oral drug in a global Phase 3 trial for Stargardt disease, a progressive inherited retinal disease with no FDA-approved therapy. It gives Tarsus a second late-stage franchise beyond XDEMVY, though topline data is not expected until 2029.

How did Tarsus do in its latest quarter?

+

In Q3 2026 (reported November 3) Tarsus posted record XDEMVY net product sales of about $194.6 million, up nearly 64% year over year, and raised its full-year 2026 XDEMVY guidance to $715 to $730 million. The net loss was about $668 million, or $0.87 per share, versus a consensus loss near $1.77, mostly from about $632 million of acquired in-process R&D charges. Cash was about $310 million at quarter end.

How has TARS stock performed in 2026?

+

As of the November 20, 2026 close of $74.50, TARS was down about 8% year to date and about 3% over twelve months, after trading as high as $91.53 and as low as $53.89 over the past year. It rose about 9% in the month before this update, a period that included the record third quarter, the raised guidance and price-target increases from Mizuho and Oppenheimer.

Why did Tarsus report a $668 million loss in Q3 2026?

+

Most of the third-quarter 2026 loss came from about $632 million of acquired in-process R&D charges tied to the Alkeus and Irenix acquisitions. Under US accounting rules, the cost of buying unapproved drug programs is expensed immediately, so it lands in one quarter as a non-cash charge. XDEMVY sales of about $195 million in the same quarter were a record.

Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with Tarsus Pharmaceuticals, Inc.'s investor relations page or your broker before making investment decisions.